SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD
SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Cognitive Neurology Consultation — Sugar Ray Robinson — True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.
| Patient | Sugar Ray Robinson |
|---|
| Date of birth | 1921-05-03 |
|---|
| Identifiers | MRN HR-BX003-SYN-TD; SSN (made up) 000-03-9318 |
|---|
| Document date | 1984-07-21 |
|---|
| Author | Mireille Haddad-Kowalski, MD |
|---|
| Custodian | St. Posthumous Health Center |
|---|
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Reason for Referral
Two years of progressive memory loss with getting lost while driving in a retired professional boxer of 63 with type 2 diabetes and hypertension; MoCA 18. Please stage the impairment, weigh Alzheimer's disease against traumatic encephalopathy syndrome and vascular disease, advise on biomarker testing and on eligibility for anti-amyloid therapy, and help us plan safety and support. [S]
Urgency: Routine; at the memory clinic two weeks from now, on the same day as his two-week primary care visit, with brain MRI and audiometry that morning. [S]
Questions for the consultant:
- What is the stage of his impairment, and is the pattern most consistent with Alzheimer's disease?
- How should we think about traumatic encephalopathy syndrome and chronic traumatic encephalopathy after his boxing career, and about vascular disease?
- Which biomarker test do you advise, and should APOE genotyping be done?
- Is he a candidate for lecanemab or donanemab under the appropriate use recommendations?
- What do you advise for symptomatic treatment, driving, firearm safety, hearing and support for his care partner?
History of Present Illness
Sugar Ray Robinson, a retired professional boxer of 63, is seen at the memory clinic with his care partner at the request of Dr. Pryce-Okonjo. He says his memory is not what it was but that this is normal at his age; his care partner describes two years of slowly worsening forgetfulness for recent events, repeated questions and stories, missed bills, and two episodes of getting lost while driving in familiar streets. There has been no sudden change, no hallucinations, no acting out of dreams, no falls and no change in personality, temper or mood. He boxed for about 25 years; he remembers many hard fights but cannot say how often he was dazed. He exercises daily and still goes to the gym of the youth foundation he started. [S]
Historical basis. These claims are historical evidence, not findings from a modern examination.
- He was born Walker Smith Jr. on May 3, 1921. The Michigan Sports Hall of Fame gives his birthplace as Ailey, Georgia, with the family later moving to Detroit; the 1989 UPI obituary says he was born in Detroit. [D]
- As a boy he moved with his family to Harlem in New York, and he won the Golden Gloves featherweight title in 1939. [D]
- He held the world welterweight championship, won in 1946, and the world middleweight title five times, first in 1951. [D]
- He boxed professionally from 1940 to 1965, about 200 bouts in all: the 1989 UPI obituary counts 201 fights, 109 won by knockout and 65 by decision; the 1987 UPI report gives a record of 174-19-6 and the Michigan Sports Hall of Fame 173-19-6. [D]
- After boxing he settled in Los Angeles, living modestly in the top story of a duplex on West Adams Boulevard, and in 1969 founded the Sugar Ray Robinson Youth Foundation for inner-city children in the Los Angeles area. [D]
- The project roster describes his dementia as probable boxing-related dementia pugilistica; no source read records that diagnosis, chronic traumatic encephalopathy, or an autopsy finding. [R]
4 later historical claims are omitted because they describe events after the index age. See the teaching note.
Allergies and Intolerances
| Allergy | Reaction | Status | Evidence |
|---|
| No known allergy | | active | S |
Medications
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|
| Metformin 1,000 mg oral tablet, one tablet twice daily with meals | One tablet twice daily with meals | Oral route | 1982-03-01 | active | S |
| Glipizide 5 mg oral tablet, one tablet before breakfast | One tablet before breakfast | Oral route | 1983-01-15 to 1984-08-18 | completed | S |
| Lisinopril 20 mg oral tablet, one tablet daily | One tablet daily | Oral route | 1981-06-01 | active | S |
| Atorvastatin 20 mg oral tablet, one tablet daily | One tablet daily | Oral route | 1982-03-01 | active | S |
| Diphenhydramine 25 mg oral capsule, one at bedtime for sleep, bought over the counter | One capsule at bedtime | Oral route | 1983-10-01 to 1984-07-07 | stopped | S |
Problems
| Problem | Clinical status | Verification | Code | Provenance |
| Memory loss over about two years, worse in the past six months, with repeated questions, missed appointments and bills, and getting lost twice while driving in familiar streets, reported by him and his care partner; cause to be found | active | confirmed |
R41.3 | S — Synthetic presenting problem anchored to his documented Alzheimer's disease; resolved into the diagnosis at the third visit. Not a claim about his real symptoms at that age. |
| Type 2 diabetes for about ten years on metformin and glipizide; hemoglobin A1c 6.4%, below his goal, with hypoglycemia risk from the sulfonylurea | active | confirmed |
E11.9 | S — Synthetic modern diabetes anchored to his documented diabetes. |
| Hypertension, controlled on lisinopril | active | confirmed |
I10 | S — Synthetic modern hypertension anchored to the single press report. |
| Bilateral sensorineural hearing loss, mild to moderate, high frequencies, on audiometry | active | confirmed |
H90.3 | S — Synthetic finding checked as a modifiable contributor to cognitive difficulty. |
Physical Exam
Vital signs recorded on 1984-07-21; see the referring visit's Vital Signs section. [S]
| System | Finding |
|---|
| Neurological | Cranial nerves normal; no rigidity, tremor, bradykinesia or dysarthria; normal strength, reflexes and coordination; steady narrow-based gait |
| Mental status | Alert and courteous; repeats questions; impaired delayed recall that cueing helps little; mild executive slowing; language and visuospatial copying preserved; no psychotic symptoms |
Results
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
| 1984-07-21 | Mini-Mental State Examination [MMSE] | 22 | {score} | | | S |
| 1984-07-21 | Clinical Dementia Rating scale [CDR] | 1 | {score} | | | S |
Assessment
- Stage and pattern (R41.3). Mild dementia (global CDR 1, MMSE 22, MoCA 18) with an amnestic presentation and progressive course, independent in personal care but dependent for complex tasks. With bilateral hippocampal atrophy, this is most consistent with Alzheimer's disease beginning before 65. Depression, thyroid disease, B12 deficiency and anticholinergic drugs have been excluded or addressed; sleep apnea risk is low; hearing loss is a treatable contributor. [S]
- Traumatic encephalopathy syndrome and vascular disease (R41.3). Twenty-five years of professional boxing is substantial exposure to repetitive head impacts. Under the 1979 NINDS consensus criteria, traumatic encephalopathy syndrome is a research diagnosis for people with that exposure and progressive cognitive or neurobehavioral impairment; it is not meant to guide routine clinical care, and the underlying disease, chronic traumatic encephalopathy, can be confirmed only after death. He has no neurobehavioral dysregulation or parkinsonism, and the amnestic pattern with hippocampal atrophy points to Alzheimer's disease; repetitive head impacts may still add to his difficulty, as the microbleeds and cavum septi pellucidi suggest past injury. Vascular change is slight and does not explain his dementia. [S]
- Biomarkers and APOE. Confirming Alzheimer's pathology will settle the diagnosis, which he wants, inform counseling and planning, and distinguish it from a mainly traumatic process. Amyloid PET is the test I advise. APOE genotyping informs the risk of amyloid-related imaging abnormalities for anti-amyloid therapy; since he is not a candidate, it would not change his care, and it carries implications for relatives. It can be offered with genetic counseling if he wishes. [S]
- Anti-amyloid therapy. By stage and MMSE (20 to 30 for donanemab, 22 to 30 for lecanemab) he would otherwise fit, and he takes no anticoagulant. But both the lecanemab and donanemab appropriate use recommendations exclude people with more than four cerebral microbleeds on the pre-treatment MRI because of the risk of bleeding and amyloid-related imaging abnormalities. With six microbleeds he does not qualify, whatever his amyloid status. [S]
- Diabetes and blood pressure (E11.9). Hemoglobin A1c 6.4% on glipizide is tighter than needed: for an older adult with cognitive impairment the ADA Standards advise a goal under 8.0% and avoiding drugs that cause hypoglycemia, which harms memory and raises the risk of falls. Blood pressure is well controlled. [S]
- Treatment, safety and support. If amyloid is confirmed, a cholinesterase inhibitor offers modest benefit: donepezil 5 mg, then 10 mg after four to six weeks if tolerated, after a baseline ECG, watching for nausea, loose stools, vivid dreams and a slow pulse. Memantine is for moderate dementia. With CDR 1 and getting lost while driving, his driving risk is high and he should not drive. A firearm should not be kept in the home of a person with dementia. Hearing aids, exercise, social activity and support for his care partner, including respite, matter as much as medicine. [S]
Data reviewed: Dr. Pryce-Okonjo's intake note. MoCA 18 at intake (education point included); PHQ-9 4; Functional Activities Questionnaire 11. Blood count, metabolic panel, B12, TSH and urine albumin-to-creatinine ratio normal; hemoglobin A1c 6.4%. Brain MRI this morning: moderate bilateral hippocampal atrophy, left more than right, mild generalized atrophy, Fazekas 1 white matter change, six microbleeds at the gray-white junction of both frontal lobes and the right temporal lobe, no cortical superficial siderosis or infarct, and a cavum septi pellucidi. Audiometry this morning: mild to moderate bilateral high-frequency sensorineural hearing loss. No anticoagulant or antiplatelet drug. Today: MMSE 22; global CDR 1, sum of boxes 5.5. [S]
Plan of Treatment
- Amyloid PET to confirm Alzheimer's disease pathology; disclosure of the result with his care partner present if he wishes. [S]
- Not a candidate for lecanemab or donanemab: more than four microbleeds on MRI; APOE genotyping not needed for treatment and offered only with genetic counseling. [S]
- Traumatic encephalopathy syndrome recorded as a consideration only; it is a research diagnosis and does not change treatment. [S]
- If amyloid is positive: donepezil 5 mg after a baseline ECG, raised to 10 mg after four to six weeks if tolerated; step back to 5 mg, or take it in the morning, for nausea, diarrhea, vivid dreams or a slow pulse. [S]
- Stop glipizide and keep metformin, with a hemoglobin A1c goal under 8.0%. [S]
- No driving; remove the firearm from the home. [S]
- Hearing aids for both ears. [S]
- Care partner education and respite, with the Alzheimer's Association 24/7 Helpline and an adult day program; the GUIDE dementia care model once he has Medicare. [S]
- Advance care planning soon, while he can take part fully. [S]
- MoCA and CDR yearly, or sooner with change; repeat MRI only for an acute change. [S]
- Discussed with Dr. Pryce-Okonjo, who saw him the same day. The findings were explained to him and his care partner; he agreed to the amyloid PET, declined APOE testing, and agreed not to drive until the results visit. [S]
- Follow-up: Dr. Pryce-Okonjo will review the PET result with him at the six-week visit and continue his care; the memory clinic will see him again in a year, or sooner if he declines faster than expected or behavioral symptoms appear. [S]